PE20061076A1 - Derivados de isoxazolina como agentes inhibidores de la caspasa y procedimiento para su preparacion - Google Patents
Derivados de isoxazolina como agentes inhibidores de la caspasa y procedimiento para su preparacionInfo
- Publication number
- PE20061076A1 PE20061076A1 PE2006000221A PE2006000221A PE20061076A1 PE 20061076 A1 PE20061076 A1 PE 20061076A1 PE 2006000221 A PE2006000221 A PE 2006000221A PE 2006000221 A PE2006000221 A PE 2006000221A PE 20061076 A1 PE20061076 A1 PE 20061076A1
- Authority
- PE
- Peru
- Prior art keywords
- procedure
- preparation
- inhibiting agents
- caspase
- isoxazoline derivatives
- Prior art date
Links
- 102000011727 Caspases Human genes 0.000 title abstract 2
- 108010076667 Caspases Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000002547 isoxazolines Chemical class 0.000 title 1
- -1 ISOQUINOLINYL Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical group [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE ISOXAZOLINA DE FORMULA (1), DONDE R1 ES ALQUILO O ARILO Y R2 ES ALQUILO, DE PREFERENCIA R1 ES ISOQUINOLINILO, QUINOLINILO O NAFTILO Y R2 ES METILO, ETILO, PROPILO O BUTILO. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE LA CASPASA, REGULANDO LA INFLAMACION Y APOPTOSIS PROVOCADA POR DICHA ENZIMA Y ES UTIL PARA EL TRATAMIENTO DE LA ARTRITIS REUMATOIDE, ENFERMEDAD INTESTINAL INFLAMATORIA, OSTEOARTRITIS, SALPINGITIS, ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20050016203 | 2005-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061076A1 true PE20061076A1 (es) | 2006-12-27 |
Family
ID=36927605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000221A PE20061076A1 (es) | 2005-02-26 | 2006-02-24 | Derivados de isoxazolina como agentes inhibidores de la caspasa y procedimiento para su preparacion |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8044080B2 (es) |
| EP (1) | EP1851214B1 (es) |
| JP (1) | JP4961357B2 (es) |
| KR (1) | KR100774999B1 (es) |
| CN (1) | CN101128459B (es) |
| AP (1) | AP2374A (es) |
| AR (1) | AR055314A1 (es) |
| AU (1) | AU2006217293B2 (es) |
| BR (1) | BRPI0607330B1 (es) |
| CA (1) | CA2598347C (es) |
| DK (1) | DK1851214T3 (es) |
| EA (1) | EA013005B1 (es) |
| ES (1) | ES2394480T3 (es) |
| IL (1) | IL185226A0 (es) |
| MA (1) | MA29311B1 (es) |
| MX (1) | MX2007010338A (es) |
| MY (1) | MY149181A (es) |
| NO (1) | NO341347B1 (es) |
| NZ (1) | NZ560805A (es) |
| PE (1) | PE20061076A1 (es) |
| PL (1) | PL1851214T3 (es) |
| PT (1) | PT1851214E (es) |
| SG (1) | SG156689A1 (es) |
| SI (1) | SI1851214T1 (es) |
| TW (1) | TWI377205B (es) |
| UA (1) | UA94395C2 (es) |
| WO (1) | WO2006090997A1 (es) |
| ZA (1) | ZA200707202B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101299720B1 (ko) * | 2006-08-16 | 2013-08-28 | 주식회사 엘지생명과학 | 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법 |
| KR20090099886A (ko) * | 2008-03-18 | 2009-09-23 | 주식회사 엘지생명과학 | 캐스파제 저해제의 프로드럭 |
| AR072181A1 (es) * | 2008-07-11 | 2010-08-11 | Gilead Sciences Inc | Metodo de tratamiento y composiciones farmaceuticas que comprenden (r)-n-((2s,3s)-2-(fluorometil)-2-hidroxi-5-oxo-tetrahidrofuran-3-il)-5-isopropil-3-(isoquinolin-1-il)-4,5-dihidroisoxazol-5-carboxamida y uso |
| TW201012816A (en) * | 2008-07-11 | 2010-04-01 | Gilead Sciences Inc | Method of treatment and pharmaceutical compositions |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US9510598B2 (en) * | 2012-09-28 | 2016-12-06 | Bayer Cropscience Ag | Nitrogen-containing heterocyclic compounds for plant disease control |
| JP2017095353A (ja) * | 2014-03-27 | 2017-06-01 | 日本曹達株式会社 | イソオキサゾリン−５−カルボキサミド化合物および有害生物防除剤 |
| WO2018133870A1 (zh) * | 2017-01-23 | 2018-07-26 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
| ES2980695T3 (es) * | 2019-04-19 | 2024-10-02 | Lg Chemical Ltd | Profármaco de inhibidor de caspasas |
| JP7442914B2 (ja) * | 2019-04-30 | 2024-03-05 | エルジー・ケム・リミテッド | カスパーゼ阻害剤のプロドラッグ |
| JP7362184B2 (ja) * | 2019-05-31 | 2023-10-17 | エルジー・ケム・リミテッド | カスパーゼ阻害剤プロドラッグの注射用組成物 |
| WO2020242234A1 (ko) * | 2019-05-31 | 2020-12-03 | 주식회사 엘지화학 | 캐스파제 저해제 프로드럭을 함유하는 주사용 조성물 및 이의 제조 방법 |
| WO2022030987A1 (ko) * | 2020-08-05 | 2022-02-10 | 주식회사 엘지화학 | 캐스파제 저해제의 골관절염 완화 또는 치료에서의 용도 |
| US20230414601A1 (en) | 2020-11-30 | 2023-12-28 | Lg Chem, Ltd. | Injectable composition containing caspase inhibitor, and preparation method therefor |
| KR102670554B1 (ko) * | 2022-01-04 | 2024-05-30 | 주식회사 이노보테라퓨틱스 | 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물 |
| JP2025502488A (ja) | 2022-01-24 | 2025-01-24 | エルジー・ケム・リミテッド | イソキサゾリン誘導体を含む注射用製剤 |
| CN118574603A (zh) * | 2022-02-23 | 2024-08-30 | 株式会社Lg化学 | 包含异𫫇唑啉衍生物的注射制剂及其制备方法 |
| US20250195500A1 (en) | 2022-03-24 | 2025-06-19 | Lg Chem, Ltd. | Injectable preparation comprising isoxazoline derivative, and preparation method therefor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19990079267A (ko) * | 1998-04-03 | 1999-11-05 | 성재갑 | 이소옥사졸(또는 이소옥사졸린) 구조를 갖는 파네실 전이효소억제제 |
| KR100373375B1 (ko) * | 1998-04-03 | 2003-06-12 | 주식회사 엘지생명과학 | 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제 |
| WO2001021600A1 (en) * | 1999-09-17 | 2001-03-29 | Lg Chem Investment Ltd. | Caspase inhibitor |
| WO2001021599A1 (en) * | 1999-09-17 | 2001-03-29 | Lg Chemical Ltd. | Caspase inhibitor |
| US7446127B2 (en) * | 2003-08-27 | 2008-11-04 | Sk Holdings Co, Ltd. | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| KR100594544B1 (ko) | 2003-08-27 | 2006-06-30 | 주식회사 엘지생명과학 | 이소옥사졸린 구조를 갖는 캐스파제 저해제 |
-
2006
- 2006-02-10 KR KR1020060013107A patent/KR100774999B1/ko active Active
- 2006-02-15 TW TW095105039A patent/TWI377205B/zh active
- 2006-02-21 NZ NZ560805A patent/NZ560805A/en unknown
- 2006-02-21 JP JP2007556969A patent/JP4961357B2/ja active Active
- 2006-02-21 SI SI200631425T patent/SI1851214T1/sl unknown
- 2006-02-21 PL PL06716026T patent/PL1851214T3/pl unknown
- 2006-02-21 CN CN2006800059846A patent/CN101128459B/zh active Active
- 2006-02-21 BR BRPI0607330-1A patent/BRPI0607330B1/pt active IP Right Grant
- 2006-02-21 DK DK06716026.7T patent/DK1851214T3/da active
- 2006-02-21 EP EP06716026A patent/EP1851214B1/en active Active
- 2006-02-21 SG SG200907192-9A patent/SG156689A1/en unknown
- 2006-02-21 AP AP2007004103A patent/AP2374A/xx active
- 2006-02-21 MX MX2007010338A patent/MX2007010338A/es active IP Right Grant
- 2006-02-21 US US11/816,801 patent/US8044080B2/en active Active
- 2006-02-21 PT PT06716026T patent/PT1851214E/pt unknown
- 2006-02-21 WO PCT/KR2006/000576 patent/WO2006090997A1/en not_active Ceased
- 2006-02-21 CA CA2598347A patent/CA2598347C/en active Active
- 2006-02-21 ES ES06716026T patent/ES2394480T3/es active Active
- 2006-02-21 AU AU2006217293A patent/AU2006217293B2/en active Active
- 2006-02-21 EA EA200701810A patent/EA013005B1/ru unknown
- 2006-02-21 UA UAA200709610A patent/UA94395C2/ru unknown
- 2006-02-22 MY MYPI20060748A patent/MY149181A/en unknown
- 2006-02-24 AR ARP060100679A patent/AR055314A1/es active IP Right Grant
- 2006-02-24 PE PE2006000221A patent/PE20061076A1/es active IP Right Grant
-
2007
- 2007-08-13 IL IL185226A patent/IL185226A0/en active IP Right Grant
- 2007-08-17 MA MA30152A patent/MA29311B1/fr unknown
- 2007-08-24 ZA ZA200707202A patent/ZA200707202B/xx unknown
- 2007-09-26 NO NO20074895A patent/NO341347B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20061076A1 (es) | Derivados de isoxazolina como agentes inhibidores de la caspasa y procedimiento para su preparacion | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| EA200971104A1 (ru) | Производные бензимидазола | |
| EA200802058A1 (ru) | Производные циклоалкиламинокислот и их фармацевтические композиции | |
| EA200802050A1 (ru) | Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов | |
| EA201000642A1 (ru) | 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы | |
| EA201001414A1 (ru) | Производные азетидина и их применение | |
| EA200970156A1 (ru) | Пиридизиноновые производные | |
| EA201070186A1 (ru) | Способы и соединения, предназначенные для получения ингибиторов котранспортера натрий-глюкозы 2 типа | |
| EA201791254A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| EA201001682A1 (ru) | Производные фенил- и бензодиоксинилзамещенных индазолов | |
| BRPI0915692B8 (pt) | compostos derivados de 1,2,5-oxadiazóis, sua forma sólida, sua composição, bem como seus usos | |
| EA200800321A1 (ru) | Ингибиторы гистондеацетилазы | |
| EA201101583A1 (ru) | Ингибиторы pi3 киназы или mtor | |
| UY31065A1 (es) | Heterociclos ciclicos | |
| EA200500203A1 (ru) | Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат | |
| UA97834C2 (ru) | Производные сульфониламида для лечения анормального роста клеток | |
| CY1110900T1 (el) | Χημικες ενωσεις | |
| DK1853588T3 (da) | Kemiske forbindelser | |
| CO6341581A2 (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| PA8601001A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
| BRPI0809542A8 (pt) | Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos | |
| EA200601273A1 (ru) | Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| CY1109569T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |